AR and prostate cancer: Our findings suggest that androgen-activated AR can downregulate CHRM4 expression by directly binding to and suppressing CHRM4. Overexpression of CHRM4 in prostate cancer cells after ADT may promote migration, invasion, and proliferation, especially in the progression of NED.